As expected based on the biology of IL-6, and its role in GCA, IL-6 inhibition by the anti-IL-6 receptor antibody tocilizumab is effective in GCA that has been verified by biopsy or large vessel imaging, and enables rapid GC tapering with reduced risk of relapse (13). The gene discussed is IL6; the disease is temporal arteritis.